Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.49

€0.49

-9.430%
-0.05
-9.430%
-
 
24.05.24 / Tradegate WKN: A12BXW / Symbol: BCLI / Name: Brainstorm Cell / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Brainstorm Cell Stock

Heavy losses for Brainstorm Cell today as the stock fell by -€0.050 (-9.430%).
So far the community has only identified positive things for Brainstorm Cell stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Brainstorm Cell Therapeutics Inc. (Symbol: BCLI) is a biotechnology company specializing in the development of innovative adult stem cell therapies for central nervous system (CNS) diseases and disorders. Headquartered in New York, the company is dedicated to leveraging its proprietary NurOwn platform, which uses autologous, patient-derived cells to treat neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). By enhancing the cells' ability to secrete neurotrophic factors (NTFs) that support nerve cells' growth, survival, and function, Brainstorm Cell is at the forefront of clinical research to address the unmet need for therapies in this rapidly evolving field. As a publicly traded company, BCLI is listed on the Nasdaq stock exchange, offering prospective investors a unique opportunity to invest in a pioneering biotech company aiming to transform the lives of millions living with neurodegenerative diseases.

Pros and Cons of Brainstorm Cell in the next few years

Pros
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Brainstorm Cell vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Brainstorm Cell -9.430% 1.873% -1.608% -81.735% 110.991% -83.003% -
Ardelyx Inc. -10.570% -13.495% 3.392% 89.573% 7.578% 9.088% -
Evolus Inc -5.830% -8.130% 6.604% 32.164% 24.862% 51.678% -
Salarius Pharmaceuticals Inc. 5.580% 0.971% -2.804% -69.412% -25.045% -98.384% -99.993%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-29

Looking at the overall financial health of Brainstorm Cell Therapeutics, symbolized as BCLI within the Biotechnology & Medical Research industry, it is evident that the company has experienced a challenging financial period in recent years. The financial data suggests a declining trend with significant losses and negative net income figures, indicating the company is not profitable.

Investing in companies like BCLI, which specialize in research and development, often means betting on potential future success. Highlighting the positives, the data suggests an increase in research and development expenditure over three years (from 2020 to 2022), supporting the idea that the company is heavily investing in their products' development. This effort could potentially lead to breakthroughs that would significantly increase the company's revenue and profitability.

Impressively, the company's capital stock remains consistent over the years—indicating that no extra shares have been issued that would dilute the value for existing shareholders. Even more, BCLI has managed to increase its capital via financing activities, as demonstrated in the cash flow statements, pointing to possible investor confidence and interest in the company's potential.

Comments

Prediction Buy
Perf. (%) -77.30%
Target price 9.188
Change
Ends at 31.03.24

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) had its price target raised by analysts at Maxim Group from $5.00 to $10.00. They now have a "buy" rating on the stock.
Ratings data for BCLI provided by MarketBeat
Show more

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for BCLI provided by MarketBeat
Show more

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for BCLI provided by MarketBeat
Show more